You are here

Building an Autonomous Glycemic Control System for Hyperglycemia of Critical Illness

Award Information
Agency: Department of Defense
Branch: Defense Advanced Research Projects Agency
Contract: W911NF19C0017
Agency Tracking Number: D18C-004-0042
Amount: $224,995.60
Phase: Phase I
Program: STTR
Solicitation Topic Code: ST18C-004
Solicitation Number: 18.C
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-03-22
Award End Date (Contract End Date): 2020-01-21
Small Business Information
8 Saint Mary's Street Suite 624
Boston, MA 02215
United States
DUNS: 080018506
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Mike Rosinko
 VP, R&D
 (714) 365-4843
Business Contact
 Edward Raskin
Phone: (949) 293-2076
Research Institution
 Boston University
 Edward Damiano Edward Damiano
One Silber Way
Boston, MA 02215
United States

 (617) 353-9493
 Nonprofit College or University

It is well established that hyperglycemia of critical illness, general glucose intolerance, and insulin resistance are common among critically ill patients, including those without a diagnosis of diabetes mellitus upon hospital admission. Such glycemic dysregulation has been linked to increased patient morbidity and mortality, and longer recovery times. Furthermore, tight glycemic control has been shown to reduce morbidity and mortality, and to shorten recovery times. However, the current standard-of-care methods for glycemic control in the critical care and general ward settings are unable to achieve tight glycemic control while simultaneously avoiding hypoglycemia, which is an independent risk factor for death in the critical care environment. Our objective is to design, build, and test a fully automated, fully integrated, bedside, closed-loop, portable glycemic control system for deployment in the critical care and general ward settings. This system would utilize peristaltic pumps for automated, intravenous insulin and dextrose administration and measure glucose levels with a body-worn sensor. The scope of this Phase I proposal includes the construction of two such prototype systems and bench-top verification testing of both systems against design requirements. Phase II efforts would involve the start of validation testing in an exploratory first-in-human clinical trial.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government